Vascular endothelial growth factor: the good, the bad, and the ugly.
D. Uhlmann
DOI: https://doi.org/10.1097/01.TP.0000229429.05420.3A
2006-08-27
Transplantation
Abstract:D iscovered in the late 1970s as a secretory product of tumor cells and characterized as a potent vascular permeability factor (VPF), the vascular endothelial growth factor (VEGF) was soon found to play a physiological role in angiogenesis and, thus, set the stage for the exciting drama in vascular biology of the 1990s. The discrepance in terminology (VPF/ VEGF) reflects well on paradoxical effects of this growth factor, its role in the disease processes, and emerging paradigms in therapeutic trials to suppress or enhance its action. VEGF is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and for reproductive functions. The VEGF family consists of six VEGF molecules designated A, B, C, D, and E and the placenta growth factor (PIGF). VEGF-A is the best characterized of these factors. It is expressed in different isoforms derived from alternative splicing of the mRNA. The smaller isoforms, VEGF-121, VEGF145, and VEGF-165 (numbers denote number of amino acids), are secreted while the larger isoforms, VEGF-189 and VEGF-205, are cell bound. The receptors for VEGF possess tyrosine kinase activity and are expressed almost exclusively on endothelial cells. The current nomenclature for the VEGF receptors lists three receptors: VEGFR-1 (flt-1), VEGFR-2 (kdr/flk-1), and VEFGR-3 (flt-4). In addition, co-receptors for some members of the VEGF family, neuropilin-1 and neuropilin-2, have been discovered. VEGF is essential for establishing a functional vascular system during embryogenesis. Deletion of a single VEGF allele results in abnormal blood vessel development and lethality in murine embryos. VEGF inactivation during early postnatal development has been shown to be lethal as well. The importance of VEGF for endochondral bone formation (the mechanism by which bone grows longitudinally) has been proven in an animal model that showed a growth restriction after VEGF inhibition. In adults, VEGF has limited physiological activities. Studies in mice indicate that disruption of VEGF is not associated with any apparent abnormalities. Its function appears to be limited to wound healing (new blood vessels transport nutrients and oxygen to the growing tissues, allowing inflammatory cells to the site of injury via the endothelial basement membrane), reproductive follicular growth and development of the corpus luteum (depend on the proliferation of new capillary vessels). The potential benefit of VEGF for therapeutic angiogenesis has been evaluated in studies administering the VEGF protein, such as in patients with limited options for coronary revascularization, as well as in gene therapy trials for patients with severe coronary artery disease and myocardial ischemia (for review, see [1]). Given the role of VEGF as a key mediator of normal physiological angiogenesis, abnormalities of VEGF expression have the potential to be important in disease processes. A large body of evidence supports the role of VEGF in the pathogenesis of diseases characterized by neovascularization, including ocular diseases and inflammatory conditions. Additionally, biopsies representing a large number of tumor types have been shown to overexpress VEGF, and, therefore, VEGF has been recognized to be fundamental to tumorigenesis and disease progression in a wide range of human cancers. Without an adequate vascular supply, solid tumors can grow only to a critical size of 1 to 2 mm (or about 10 cells), primarily due to lack of oxygen and nutrients. Folkman (1971) hypothesized that tumor blood vessel formation is dependent on a tumor angiogenic factor (TAF), and that its blockade during the period when a tumor is most vulnerable (i.e. prior to angiogenesis) may restrict tumor growth (2). VEGF was later identified as one of the most potent TAF molecules. Tumors may remain dormant, in an avascular phase, maintaining a steady state between cell proliferation and apoptosis before converting to an angiogenic phenotype. This conversion, which is known as the “angiogenic switch,” is due to an alteration in the balance of inhibitory and stimulatory factors. Preliminary evidence suggests that overexpression of certain isoforms of VEGF may cause different effects on tumor angiogenesis. VEGF-165 seems to be the predominant isoform in most tumors. Several factors have been shown to up-regulate VEGF expression including hypoxia, low pH, growth factors, intrinsic up-regulation of signal transduction pathways, and loss of tumor suppressor gene activity. Several studies have also demonstrated that VEGF is expressed in tumor-associated stromal cells, where it is probably upregulated by environmental conditions caused by the tumor. Increased VEGF expression correlates with poor prognosis, including aggressive tumor growth, tumor recurrence, tumor metastasis and decreased survival, in many tumor types including colon cancer, gastric carcinoma, nonDepartment of Visceral, Transplantation, Thoracic and Vascular Surgery, University of Leipzig, Germany. Address correspondence to: Dirk Uhlmann, M.D., 2nd Department of Surgery, University of Leipzig, Liebigstr. 20, 04103 Leipzig, Germany. E-mail: uhld@medizin.uni-leipzig.de Received 2 April 2006. Revision requested 4 April 2006. Accepted 5 April 2006. Copyright © 2006 by Lippincott Williams & Wilkins ISSN 0041-1337/06/8204-450 DOI: 10.1097/01.tp.0000229429.05420.3a